Translational Awards
Funds translational research to advance innovative cardiovascular technologies from proof-of-concept to commercial readiness, focusing on strong IP, milestone-driven plans, and unmet clinical needs.
Funder: British Heart Foundation
Due Dates: February 4, 2026 (Preliminary) | August 5, 2026 (Preliminary)
Funding Amounts: No upper limit; typically up to 3 years with milestone-based budgets
Summary: Supports the development of innovative cardiovascular technologies from proof-of-concept to commercial readiness, focusing on projects with strong IP and commercialisation potential.
Key Information: Preliminary application required; must partner with your institution’s Technology Transfer Office.
Description
This opportunity funds translational research to advance novel technologies with the potential to improve human cardiovascular health, moving them from the proof-of-concept stage toward commercial market readiness. Projects should have a strong intellectual property position, a credible development plan, and the potential to attract further investment. Eligible projects may include initial development, pre-clinical studies, and early phase clinical trials (up to phase II), provided they reach a significant scientific or value inflection milestone. The scheme welcomes applications addressing unmet clinical needs across a broad range of technology types—therapeutics, devices, diagnostics, digital solutions, and regenerative medicine. All projects must be milestone-driven, structured, and include a clear route to market and regulatory strategy. Close collaboration with your institution’s Technology Transfer Office is required to develop the IP and commercialisation case.
